Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Fairooz Kabbinavar, M.D., F.A.C.P.
Fairooz Kabbinavar, M.D., F.A.C.P.


Medical Oncology

General Information:



Professor, Department of Medicine, Hematology/Oncology
Henry Alvin and Carrie L. Meinhardt Endowed Chair in Kidney Cancer Research
Medical Director Thoracic Oncology and Kidney Cancer Programs
Co-Director- Hematology-Oncology Fellowship Program
Member, JCCC Signal Transduction and Therapeutics Program Area


Hematology-Oncology, UCLA School of Medicine, 1991-1994
Internal Medicine, Beth Israel Deaconess Medical Center-East Campus, 1987 - 1989
Internal Medicine, Beth Israel Deaconess Medical Center-East Campus, 1986 - 1987
Medical Degree:
M.D., University of Nagpur Faculty of Medicine, 1979


Board Certification(s):
Medical Oncology, American Board of Internal Medicine, 1997, 2007
Internal Medicine, American Board of Internal Medicine, 1992

Contact Information:

(310) 206-3921
(310) 206-5930 Genitourinary Oncology information and referral
(310) 206-6909 Genitourinary Oncology referring physician
(310) 206-7161 Lung Cancer Program patient appointments
(310) 206-6931 or (310) 206-6909 UCLA Oncology Center information and patient appointments

Practice Information:

Clinical Interest(s):
Kidney Cancer
Prostate Cancer
Lung Cancer
Head and Neck Cancer

Scientific Interest(s):

Dr. Fairooz Kabbinavar's research focuses on anti-tumor angiogenesis and translational work. His clinical interests lie in kidney cancer, lung cancer and head and neck cancer.

Selected Cancer-Related Publications:

Hirsch FR, Kabbinavar F, Eisen T, Martins R, Schnell FM, Dziadziuszko R, Richardson K, Richardson F, Wacker B, Sternberg DW, Rusk J, Franklin WA, Varella-Garcia M, Bunn PA, Camidge DR, Camidge R. A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer. J Clin Oncol. 2011 Sep 10;29(26):3567-73. Epub 2011 Aug 8

Blumenschein GR, Kabbinavar F, Menon H, Mok TS, Stephenson J, Beck JT, Lakshmaiah K, Reckamp K, Hei YJ, Kracht K, Sun YN, Sikorski R, Schwartzberg L. A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. Ann Oncol. 2011 Sep;22(9):2057-67. Epub 2011 Feb 14

Schöffski P, Garcia JA, Stadler WM, Gil T, Jonasch E, Tagawa ST, Smitt M, Yang X, Oliner KS, Anderson A, Zhu M, Kabbinavar F. A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma. BJU Int. 2011 Sep;108(5):679-86. Epub 2010 Dec 13

Herbst RS, Sun Y, Eberhardt WE, Germonpré P, Saijo N, Zhou C, Wang J, Li L, Kabbinavar F, Ichinose Y, Qin S, Zhang L, Biesma B, Heymach JV, Langmuir P, Kennedy SJ, Tada H, Johnson BE. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol. 2010 Jul;11(7):619-26.

Bukowski RM, Kabbinavar FF, Figlin RA, Flaherty K, Srinivas S, Vaishampayan U, Drabkin HA, Dutcher J, Ryba S, Xia Q, Scappaticci FA, McDermott D. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol. 2007 Oct 10;25(29):4536-41. Epub 2007 Sep 17